CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro)

摘要

Carcinoembryonic antigen (CEA) response may be a surrogate for response and long-term outcome in (K)RAS wild-type mCRC receiving first-line targeted therapy. FOLFIRI and cetuximab induced a greater CEA response than FOLFIRI and bevacizumab. CEA response correlated with longer survival. Hypothesizing that CEA reflects tumor burden, greater CEA response may indicate greater antitumor efficacy.To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab.